Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations
Journal of Diabetes Research · 2026-01 · 2026 (1)
DOI: 10.1155/jdr/8893769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, online erschienen am 20.03.2026. Verfasst von Zhenhan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Project of Chongqing Municipal Technological Innovation and Application Development Special Fund, Chongqing Medical Youth Top Talent Project, Chongqing Municipal Science and Health Joint Medical Research Project.
Abstract (Originalsprache)
GLP‐1 receptor agonists (GLP‐1RAs) are extensively used in treating Type 2 diabetes due to their therapeutic benefits. However, clinical reports have highlighted adverse events, particularly the underexplored association with tumor development. This study investigates GLP‐1RA–related adverse events, focusing on tumorigenic risks, using data from the FDA Adverse Event Reporting System (FAERS). FAERS data from Q1 2005 to Q4 2023 were analyzed using the proportional reporting ratio (PRR) method to identify GLP‐1RA–associated adverse events. Detailed analyses examined event distribution across genders, ages, and body weights, with an emphasis on tumor‐related risks in vulnerable subpopulations. A total of 195,250 GLP‐1RA–related adverse event reports were identified, spanning 25 system organ classes (SOCs). The most reported SOCs were gastrointestinal disorders ( n = 110,451, PRR 2.44), investigative findings ( n = 80,126, PRR 2.46), and metabolism and nutrition disorders ( n = 25,236, PRR 2.21). Notably, 7457 cases involved benign, malignant, and unspecified tumors (PRR 0.5). Further analysis revealed that the risk of GLP‐1RA–associated tumorigenesis varied by age, sex, and weight, suggesting that tumorigenesis risk differed in specific subpopulations. These findings underscore the need for vigilance regarding GLP‐1RA–related adverse events, particularly tumor risks in specific subgroups. Clinicians should consider patient‐specific factors, such as age, gender, and body weight, to ensure safe and effective GLP‐1RAs therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
- Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing Medical University, Chongqing, China, cqmu.edu.cn.
- Department of Cardiology, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.
ORCID-Profile: Zhenhan Li, Juan Xu, Jun Qian
Förderung
- Key Project of Chongqing Municipal Technological Innovation and Application Development Special Fund
- Chongqing Medical Youth Top Talent Project
- Chongqing Municipal Science and Health Joint Medical Research Project
- 4th Young Talent Project of Chongqing Traditional Chinese Medicine Hospital
- Clinical Research Project of Tongji Hospital of Tongji University
- Chongqing Postdoctoral Innovative Talents Support Program Fund
Zitieren
APA
Li, Z., Huang, J., Zhou, S., Luan, Y., Xie, H., Chen, Z., Xu, J., & Qian, J. (2026). Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Journal of Diabetes Research, 2026(1). https://doi.org/10.1155/jdr/8893769
Vancouver
Li Z, Huang J, Zhou S, Luan Y, Xie H, Chen Z, et al. Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Journal of Diabetes Research. 2026;2026(1). doi:10.1155/jdr/8893769
BibTeX
@article{Li2026,
author = {Li, Zhenhan and Huang, Jun and Zhou, Sha and Luan, Yongan and Xie, Huang and Chen, Zhongpei and Xu, Juan and Qian, Jun},
title = {Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations},
journal = {Journal of Diabetes Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jdr/8893769}
}
EUVIMED